Clinical Trials Logo

Filter by:
NCT ID: NCT01468285 Completed - Clinical trials for Gait or Balance Disorder Problems

The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow

CBF
Start date: February 2012
Phase: Phase 4
Study type: Interventional

Betahistine may provide benefit by enhancement of Cerebral Blood Flow (CBF). This placebo-controlled pharmacodynamic treatment study will primarily explore the effect of betahistine on cerebral blood flow measured by dynamic contrast-enhanced MRI imaging, in a patient population with MRI evidence of cerebrovascular compromise. Also it will be measured if CBF changes correlate with gait and cognitive changes.

NCT ID: NCT01466660 Completed - Lung Neoplasms Clinical Trials

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Start date: December 13, 2011
Phase: Phase 2
Study type: Interventional

This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients who are having epidermal growth factor receptor mutation positive advanced adenocarcinoma of the lung.

NCT ID: NCT01464918 Unknown status - Gastric Cancer Clinical Trials

Safety and Efficacy of Using MASTER to Perform Endoscopic Submucosal Dissection in Human

Start date: November 2011
Phase: N/A
Study type: Interventional

This trial is to evaluate the safety and efficacy of using MASTER, a robotics enhanced endosurgical system to perform endoscopic submucosal dissection (ESD) of gastric/colon cancer in human.

NCT ID: NCT01463306 Completed - Clinical trials for Epilepsy, Partial Seizures

A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Start date: February 21, 2012
Phase: Phase 3
Study type: Interventional

Study A0081106 is a 12-month open-label study to evaluate the long term safety and tolerability of pregabalin as add-on therapy in pediatric subjects 1 month to 16 years of age with partial onset seizures and pediatric and adult subjects 5 to 65 years of age with primary generalized tonic-clonic seizures. Pregabalin will be administered in equally divided daily doses for 1 year, in either capsule or liquid oral formulation.

NCT ID: NCT01462604 Completed - Cancer Clinical Trials

Pilot Study of Patient's Adherence to TYKERB™/TYVERB™ + Capecitabine in Metastatic Breast Cancer

Start date: November 23, 2011
Phase:
Study type: Observational

This is a 6-week, single arm, pilot study to test the study procedure, educational materials, and measurement instruments for the educational intervention in HER2 overexpressing metastatic or advanced breast cancer patients

NCT ID: NCT01462357 Completed - Clinical trials for Infections, Papillomavirus

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Start date: November 21, 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and the safety of Cervarix administered according to a 2-dose schedule at 0, 6 months compared to Gardasil, administered according to a 2-dose schedule at 0, 6 months or the standard 3-dose schedule of 0, 2, 6 months in 9-14 years old healthy females.

NCT ID: NCT01460472 Active, not recruiting - NSCLC Clinical Trials

Immunotherapy With Racotumomab in Advanced Lung Cancer

Start date: September 2010
Phase: Phase 3
Study type: Interventional

This is a prospective, randomized, open label, parallel-group, multicenter phase III study to evaluate the efficacy and safety of active specific immunotherapy with racotumomab plus best supportive care versus best supportive care in patients with advanced NSCLC who have achieved an Objective Response (Partial or Complete Response) or Stable Disease with standard first-line treatment. Also immunological parameters will be evaluated. Best supportive therapy will be administered to all patients in the study according to institutional standards and includes any subsequent onco-specific therapies. 1082 patients will be included in the study, with non-small cell lung cancer in stages IIIA (non-resectable), IIIB or IV.

NCT ID: NCT01456689 Completed - Multiple Myeloma Clinical Trials

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Start date: April 25, 2012
Phase: Phase 1
Study type: Interventional

The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with Multiple Myeloma (MM).

NCT ID: NCT01454934 Completed - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Start date: December 9, 2011
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multicenter, Phase 3 study, comparing efficacy and safety of eribulin with TPC in subjects with advanced and disease progression following at least two prior regimens for advanced disease, which should have included a platinum-based regimen.

NCT ID: NCT01453270 Completed - Sepsis Clinical Trials

Emergency Department Management of Sepsis Patients: A Goal-Oriented Non-Invasive Sepsis Trial

AGONIST
Start date: November 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the use of a 3-hour protocol utilizing non-invasive hemodynamic optimization treatment strategy results in better outcome and lower hospital costs in patients who present with severe bloodstream infections to the Emergency Department (ED).